Restriction of which electrolyte is recommended in the management of high blood pressure?

Choice A reason: Respiratory acidosis does not cause no change in affinity of hemoglobin with oxygen. It causes a decrease in affinity of hemoglobin with oxygen, which means that hemoglobin releases more oxygen to the tissues. This is known as the Bohr effect, which is a physiological response to low pH and high CO2 levels.

Choice B reason: Respiratory acidosis causes a decrease in affinity of hemoglobin with oxygen, which means that hemoglobin releases more oxygen to the tissues. This is the correct statement that describes the expected finding in this patient. The decrease in affinity of hemoglobin with oxygen is a compensatory mechanism that tries to restore the oxygen balance in the body.

Choice C reason: Respiratory acidosis does not cause an increase in affinity of hemoglobin with oxygen. It causes a decrease in affinity of hemoglobin with oxygen, which means that hemoglobin releases more oxygen to the tissues. An increase in affinity of hemoglobin with oxygen would mean that hemoglobin holds on to oxygen more tightly, which would worsen the hypoxia in the patient.

Choice D reason: Respiratory acidosis does not cause a decrease in blood CO2. It causes an increase in blood CO2, which is the primary cause of the low pH. A decrease in blood CO2 would indicate respiratory alkalosis, which is a condition of high pH and low CO2 levels.

Choice A reason: This is not a correct statement. LABAs stand for long-acting beta2-agonists, which are a class of medications that relax the smooth muscles of the airways and improve the airflow in patients with asthma or COPD. However, LABAs do not reduce the risk of asthma-related deaths, and may even increase it if used alone without an inhaled glucocorticoid, which is a type of anti-inflammatory medication.

Choice B reason: This is not a correct statement. LABAs cannot be used on an as-needed basis to treat symptoms, as they have a slow onset of action and a long duration of effect. LABAs are meant to be used as a maintenance therapy to prevent asthma exacerbations, not to relieve acute symptoms. For quick relief of symptoms, patients should use a short-acting beta2-agonist, such as albuterol or salbutamol.

Choice C reason: This is not a correct statement. LABAs are not safer than short-acting beta2 agonists, as they have similar side effects, such as tachycardia, tremors, and hypokalemia. LABAs also have a black box warning that they may increase the risk of asthma-related deaths if used without an inhaled glucocorticoid.

Choice D reason: This is the correct statement. LABAs should be combined with an inhaled glucocorticoid, as this combination has been shown to improve the asthma control, reduce the frequency and severity of exacerbations, and decrease the inflammation and airway hyperresponsiveness. The inhaled glucocorticoid also reduces the risk of adverse effects and mortality associated with LABAs.